

5.21.06

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	March 16, 2011
<b>Subject:</b>	Trastuzumab	<b>Page:</b>	1 of 5

---

**Last Review Date:** June 16, 2022

---

## Trastuzumab

### Description

Herceptin (trastuzumab), **Herzuma** (trastuzumab-pkrb), **Kanjinti** (trastuzumab-anns), **Ogivri** (trastuzumab-dkst), **Ontruzant** (trastuzumab-dttb), **Trazimera** (trastuzumab-qyyp)

The biosimilar medications in bold are the preferred products for claims adjudicated through the pharmacy benefit.

### Background

Herceptin and its biosimilars are monoclonal antibodies that selectively binds with high affinity to the Human Epidermal Growth Factor Receptor – 2 (HER2) protein. Herceptin and its biosimilars are mediators of antibody-dependent cellular cytotoxicity (ADCC). Herceptin and its biosimilars effects have been shown to be preferentially exerted on HER2-overexpressing cancer cells compared with cancer cells that do not over-express HER2. Herzuma, Kanjinti, Ogivri, Ontruzant, and Trazimera are biosimilars which means that the biological products are approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product (1-6).

### Regulatory Status

FDA-approved indication: Herceptin and its biosimilars are indicated for the adjuvant treatment of HER2 overexpressing breast cancer and the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma (1-6).

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	March 16, 2011
<b>Subject:</b>	Trastuzumab	<b>Page:</b>	2 of 5

---

Herceptin and its biosimilars carry a boxed warning regarding possible risks for cardiomyopathy, infusion reactions, pulmonary toxicity, and embryo-fetal toxicity. Trastuzumab use can result in cardiac failure that manifests as congestive heart failure (CHF) or decreased left ventricular ejection fraction (LVEF), with greatest risk when administered concurrently with anthracyclines (1).

Exposure to Herceptin or its biosimilars during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia and neonatal death. Female patients of reproductive potential should be advised to use effective contraception during treatment and for 7 months following the last dose of Herceptin or its biosimilars (1).

Safety and effectiveness in pediatric patients have not been established (1).

### Related policies

Afinitor, Enhertu, Halaven, Herceptin Hylecta, Ibrance, Kadcyca, Margenza, Nerlynx, Perjeta, Plesgo, Tukysa, Tykerb

### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Herceptin and its biosimilars may be considered **medically necessary** for patients 18 years of age or older for the treatment of HER2 overexpressing breast cancer or HER2 overexpressing metastatic or gastroesophageal junction adenocarcinoma and if the conditions indicated below are met.

Herceptin and its biosimilars may be considered **investigational** in patients under age 18 years of age and for all other indications.

## Prior-Approval Requirements

**Age** 18 years of age or older

### Diagnoses

Patient must have **ONE** of the following:

1. HER2 overexpressing breast cancer

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	March 16, 2011
<b>Subject:</b>	Trastuzumab	<b>Page:</b>	3 of 5

---

2. HER2 overexpressing metastatic gastric or gastroesophageal junction (GEJ) Adenocarcinoma

**AND ALL** of the following:

- a. HER2 protein overexpression or HER2 gene amplification as confirmed by an FDA-approved test
- b. Prescriber agrees to monitor for cardiac function and pulmonary toxicity
- c. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Trastuzumab and for 7 months following the last dose
- d. **Herceptin only**: Patient **MUST** have tried at least **TWO** of the preferred products (Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera) if adjudicated through the pharmacy benefit unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

## Prior – Approval *Renewal* Requirements

**Age** 18 years of age or older

### Diagnoses

Patient must have **ONE** of the following:

1. HER2 overexpressing breast cancer
2. HER2 overexpressing metastatic gastric or gastroesophageal junction (GEJ) Adenocarcinoma

**AND ALL** of the following:

- a. Prescriber agrees to monitor for cardiac function and pulmonary toxicity
- b. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Trastuzumab and for 7 months following the last dose
- c. **Herceptin only**: Patient **MUST** have tried at least **TWO** of the preferred products (Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera) if adjudicated through the pharmacy benefit unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	March 16, 2011
<b>Subject:</b>	Trastuzumab	<b>Page:</b>	4 of 5

---

## Pre – PA Allowance

None

## Prior - Approval Limits

**Duration** 12 months

## Prior – Approval *Renewal* Limits

Same as above

## Rationale

### Summary

Herceptin and its biosimilars are monoclonal antibodies that selectively bind with high affinity to the HER2 protein. Herceptin and its biosimilars are mediators of antibody-dependent cellular cytotoxicity (ADCC). Herceptin and its biosimilars effects have been shown to be preferentially exerted on HER2-overexpressing cancer cells compared with cancer cells that do not overexpress HER2 (1-6).

Prior approval is required to ensure the safe, clinically appropriate and cost-effective use of Herceptin and its biosimilars while maintaining optimal therapeutic outcomes.

### References

1. Herceptin [package insert]. South San Francisco, CA: Genentech, Inc.; February 2021.
2. Herzuma [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; May 2019.
3. Kanjinti [package insert]. Thousand Oaks, CA: Amgen Inc.; October 2019.
4. Ogivri [package insert]. Morgantown, WV: Mylan GmbH; February 2021.
5. Ontruzant [package insert]. Jersey City, NJ: Organon LLC; June 2021.
6. Trazimera [package insert]. New York, NY: Pfizer Inc.; November 2020.
7. NCCN Drugs & Biologics Compendium® Trastuzumab 2022. National Comprehensive Cancer Network, Inc. Accessed on April 15, 2022.

## Policy History

Date	Action
September 2012	Annual editorial and reference update
March 2013	Annual editorial and reference update

# 5.21.06

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	March 16, 2011
<b>Subject:</b>	Trastuzumab	<b>Page:</b>	5 of 5

---

June 2013	Editorial and reference update
September 2014	Annual editorial review and reference update
June 2015	Annual editorial and reference update
June 2016	Annual editorial review and reference update Policy number change from 5.04.06 to 5.21.06
June 2017	Annual editorial review
December 2017	Addition of Ogivri
March 2018	Annual Review
December 2018	Addition of biosimilar Herzuma. Changed policy name to Trastuzumab
February 2019	Addition of biosimilar Ontruzant
March 2019	Annual review and reference update. Addition of biosimilar Trazimera
June 2019	Annual review. Addition of biosimilar Kanjinti
December 2019	Annual review. Addition of requirement to trial preferred product
March 2020	Annual review and reference update
June 2020	Annual review
September 2020	Annual review
December 2020	Annual review and reference update. Added Herzuma, Ogivri, Ontruzant, Trazimera as preferred products
April 2021	Clarification added to the t/f, intolerance, C/I to preferred products requirement indicating that it only applies to claims adjudicated through the pharmacy benefit. Added requirement for cardiac and pulmonary toxicity monitoring, HER2 overexpression or gene amplification as confirmed by FDA-approved test, and for females of reproductive potential to be advised to use effective contraception to align with the Herceptin Hylecta criteria
June 2021	Annual review and reference update
June 2022	Annual review and reference update

## Keywords

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 16, 2022 and is effective on July 1, 2022.**